San Diego, CA., Oct. 2. 2012 – Concortis Biosystems , Corp., a biotech company focusing on development of novel antibody-drug conjugate (ADC) technologies, today announced the appointment of Alexander Chucholowski, Ph.D. as Chief Operating Officer.
Dr. Chucholowski brings more than 25 years of experience in the pharmaceutical and biotechnology industry to Concortis. His expertise has been focused on the rapid transformation of drug discovery innovations into marketable products and services. Following a 15-year career at Warner-Lambert/Parke-Davis where he was instrumental in the research on Lipitor and at F. Hoffmann-La Roche, he served in senior positions, including President, at ChemBridge Research Labs (CRL). Most recently Dr. Chucholowski founded RGo Bioscience LLC and was Chief Scientific Officer – responsible for the development of novel delivery technologies for oligonucleotide therapeutics - until its acquisition. He is credited with more than 45 scientific papers and patent applications.
“Dr. Chucholowski brings a powerful combination of extensive drug research and CRO business expertise to his new role at Concortis,” said President and CSO David Miao of Concortis:” We are excited to have a scientist of his caliber join our management team and look forward to him advancing Concortis to become the premier partner in serving the ADC industry.
On his appointment Dr. Chucholowski commented: “I am extremely pleased to join Concortis at a time of exciting growth of ADC therapies. The company’s platform technology is uniquely suited to identifying ADC therapeutics with optimal profiles and accelerating their development. In my new role, I look forward to positioning Concortis as a leader in providing antibody conjugation technologies and help customers and partners accelerate the development of novel therapeutics, and thus, significantly improve patients’ quality of life”.
About Concortis Biosystems, Corp.
Concortis Biosystems is a Delaware company, headquartered in San Diego, specializing in novel linker technologies, proprietary payloads (“warhead”) and conjugation services for the antibody-drug conjugate (ADC) community. Concortis provides customers with divers classes of linkers and payloads, and conjugation services as well for rapid proof-of principle studies. Concortis’ proprietary ADC technologies include, not limited to, C-LockTM and K-lockTM conjugation methods, novel linkers and bifunctional spacers, and dual active payloads such as DuostatinsTM and DuomycinsTM. Concortis recently formatted its ADC technologies to the “50-20 panels screening” platform that could save partners’ years of time and millions of dollars from target to IND. Concortis looks forward to strategic partnerships in ADC research collaborations and product developments.
